Annexon Pharmaceuticals 已将目光投向其 C1q 驱动补体抑制剂的后期临床里程碑。 Annexon Pharmaceuticals has set its sights on late-stage clinical milestones for its C1q-driven complement inhibitors.
临床阶段生物制药公司Annexon概述了其2024年的战略重点，包括治疗格林-巴利综合征的ANX005、治疗地理萎缩的ANX007以及治疗各种自身免疫适应症的口服小分子补体抑制剂ANX1502的后期临床里程碑。 Annexon, a clinical-stage biopharmaceutical company, has outlined its strategic priorities for 2024, including late-stage clinical milestones for ANX005 in Guillain-Barré syndrome, ANX007 in geographic atrophy, and the oral small molecule complement inhibitor, ANX1502, for various autoimmune indications. 该公司的产品组合是经过十多年的研究而建立的，旨在阻止影响身体、大脑和眼睛的疾病中由 C1q 驱动的炎症。 The company's portfolio has been built over a decade of research aimed at stopping C1q-driven inflammation in diseases affecting the body, brain, and eye.